SHANDONG PHARMACEUTICAL GLASS CO.LTD Financials Shandong Pharmaceutical Glass Co.Ltd
Equities
600529
CNE000001BG9
Non-Paper Containers & Packaging
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.82 CNY | -1.28% |
|
-2.42% | +8.67% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 16,445 | 29,838 | 26,119 | 18,847 | 16,989 | 18,462 | - | - |
| Enterprise Value (EV) 1 | 16,445 | 28,706 | 25,234 | 17,500 | 15,524 | 15,365 | 14,776 | 14,064 |
| P/E ratio | 35.9 x | 52.8 x | 44.3 x | 27.6 x | 21.9 x | 18.7 x | 15.9 x | 13.7 x |
| Yield | 1.09% | 0.6% | 0.68% | 1.06% | 1.56% | 1.76% | 2.06% | 2.34% |
| Capitalization / Revenue | 5.5 x | 8.71 x | 6.74 x | 4.5 x | 3.41 x | 3.29 x | 2.89 x | 2.6 x |
| EV / Revenue | 5.5 x | 8.38 x | 6.51 x | 4.18 x | 3.12 x | 2.74 x | 2.31 x | 1.98 x |
| EV / EBITDA | 21.8 x | 32.1 x | 26.9 x | 17.4 x | 12.5 x | 9.87 x | 8.09 x | 6.83 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 4.25 x | 7.01 x | 5.59 x | 2.71 x | 2.25 x | 2.27 x | 2.05 x | 1.87 x |
| Nbr of stocks (in thousands) | 594,968 | 594,968 | 594,968 | 663,614 | 663,614 | 663,614 | - | - |
| Reference price 2 | 27.64 | 50.15 | 43.90 | 28.40 | 25.60 | 28.18 | 28.18 | 28.18 |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,992 | 3,427 | 3,875 | 4,187 | 4,982 | 5,609 | 6,383 | 7,087 |
| EBITDA 1 | 755.4 | 895.2 | 938.9 | 1,006 | 1,241 | 1,557 | 1,826 | 2,058 |
| EBIT 1 | 586.3 | 677.3 | 698.3 | 711.1 | 916.4 | 1,173 | 1,381 | 1,599 |
| Operating Margin | 19.59% | 19.76% | 18.02% | 16.98% | 18.39% | 20.91% | 21.64% | 22.56% |
| Earnings before Tax (EBT) 1 | 546 | 653.5 | 688.7 | 708.1 | 910.8 | 1,168 | 1,379 | 1,596 |
| Net income 1 | 458.7 | 564.4 | 591.1 | 618.3 | 775.8 | 999.2 | 1,180 | 1,362 |
| Net margin | 15.33% | 16.47% | 15.25% | 14.77% | 15.57% | 17.82% | 18.48% | 19.22% |
| EPS 2 | 0.7700 | 0.9500 | 0.9900 | 1.030 | 1.170 | 1.504 | 1.777 | 2.052 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.3000 | 0.3000 | 0.3000 | 0.3000 | 0.4000 | 0.4962 | 0.5802 | 0.6590 |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1,012 | 1,199 | 1,237 | 1,186 | 2,422 | 1,251 | 1,308 | 1,267 | 1,334 | 1,408 | 1,472 | 1,537 | 1,474 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | 137.3 | 198.4 | 267.2 | - | 276.2 | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | 11.45% | 16.05% | 22.53% | - | 22.07% | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | 219 | 385.5 | - | - | 220.8 | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | 18.47% | 15.91% | - | - | 17.42% | - | - | - | - | - |
| EPS 2 | 0.2000 | 0.2600 | 0.2800 | 0.2900 | 0.2000 | 0.2500 | 0.3309 | - | 0.3500 | 0.2400 | 0.3300 | 0.3600 | 0.3700 | 0.3200 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/25/22 | 4/25/22 | 8/29/22 | 10/28/22 | 4/24/23 | 4/24/23 | 8/28/23 | 8/28/23 | 10/18/23 | 4/22/24 | 4/22/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,132 | 885 | 1,347 | 1,465 | 3,097 | 3,685 | 4,398 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 12.4% | 14% | 13.3% | 12.3% | 10.7% | 12.2% | 13% | 13.6% |
| ROA (Net income/ Total Assets) | 9.37% | 10.5% | - | 8.14% | - | 9.86% | 10.5% | 10.8% |
| Assets 1 | 4,897 | 5,396 | - | 7,597 | - | 10,136 | 11,263 | 12,635 |
| Book Value Per Share 2 | 6.500 | 7.150 | 7.850 | 10.50 | 11.40 | 12.40 | 13.80 | 15.10 |
| Cash Flow per Share 2 | 1.010 | 0.9500 | 1.260 | 0.3800 | 1.580 | 1.570 | 2.030 | 2.220 |
| Capex 1 | 586 | 534 | 806 | 700 | 669 | 784 | 737 | 720 |
| Capex / Sales | 19.57% | 15.58% | 20.79% | 16.71% | 13.43% | 13.97% | 11.54% | 10.15% |
| Announcement Date | 4/28/20 | 4/26/21 | 4/25/22 | 4/24/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
28.18
CNY
Average target price
35.2
CNY
Spread / Average Target
+24.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.08% | 2.58B | |
| +5.11% | 4.61B | |
| +9.59% | 3.5B | |
| -11.50% | 1.2B | |
| -20.97% | 674M | |
| 0.00% | 598M | |
| +6.25% | 373M | |
| -18.11% | 337M | |
| -32.38% | 244M | |
| -1.60% | 193M |
- Stock Market
- Equities
- 600529 Stock
- Financials Shandong Pharmaceutical Glass Co.Ltd